People · Operator
Named in public records as an officer, director or promoter · active 2009–2009 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pervasis Therapeutics Inc | — | Biotechnology | Series A | $10.0M | $361.6M | 2009 |
Peter B Hutt at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter B Hutt on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert S Langer | 1 | 14 |
| Amir Nashat | 1 | 14 |
| Frank Litvack | 1 | 3 |
| Robert F Higgins | 1 | 3 |
| Earl M Collier | 1 | 3 |
| EDWIN M. KANIA | 1 | 3 |
| Elazer R Edelman | 1 | 2 |
| Frederic Chereau | 1 | 1 |
| Helen M Nugent | 1 | 1 |
| Yoram Richter | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.